Calidi Biotherapeutics (CLDI) Competitors $5.04 -0.82 (-13.99%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$5.30 +0.26 (+5.24%) As of 08/14/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLDI vs. MLYS, ZYME, LENZ, TRVI, NRIX, XERS, PHAR, ORIC, DNA, and UPBShould you be buying Calidi Biotherapeutics stock or one of its competitors? The main competitors of Calidi Biotherapeutics include Mineralys Therapeutics (MLYS), Zymeworks (ZYME), LENZ Therapeutics (LENZ), Trevi Therapeutics (TRVI), Nurix Therapeutics (NRIX), Xeris Biopharma (XERS), Pharming Group (PHAR), Oric Pharmaceuticals (ORIC), Ginkgo Bioworks (DNA), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry. Calidi Biotherapeutics vs. Its Competitors Mineralys Therapeutics Zymeworks LENZ Therapeutics Trevi Therapeutics Nurix Therapeutics Xeris Biopharma Pharming Group Oric Pharmaceuticals Ginkgo Bioworks Upstream Bio Calidi Biotherapeutics (NYSE:CLDI) and Mineralys Therapeutics (NASDAQ:MLYS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability. Do institutionals and insiders have more ownership in CLDI or MLYS? 12.5% of Calidi Biotherapeutics shares are owned by institutional investors. Comparatively, 84.5% of Mineralys Therapeutics shares are owned by institutional investors. 6.7% of Calidi Biotherapeutics shares are owned by insiders. Comparatively, 25.6% of Mineralys Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more risk & volatility, CLDI or MLYS? Calidi Biotherapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Mineralys Therapeutics has a beta of -0.29, suggesting that its share price is 129% less volatile than the S&P 500. Does the media favor CLDI or MLYS? In the previous week, Mineralys Therapeutics had 7 more articles in the media than Calidi Biotherapeutics. MarketBeat recorded 10 mentions for Mineralys Therapeutics and 3 mentions for Calidi Biotherapeutics. Mineralys Therapeutics' average media sentiment score of 0.84 beat Calidi Biotherapeutics' score of 0.50 indicating that Mineralys Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Calidi Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mineralys Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer CLDI or MLYS? Mineralys Therapeutics has a consensus price target of $32.25, suggesting a potential upside of 128.24%. Given Mineralys Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Mineralys Therapeutics is more favorable than Calidi Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calidi Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Mineralys Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Is CLDI or MLYS more profitable? Calidi Biotherapeutics' return on equity of 0.00% beat Mineralys Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Calidi BiotherapeuticsN/A N/A -344.45% Mineralys Therapeutics N/A -70.44%-65.51% Which has stronger earnings & valuation, CLDI or MLYS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalidi BiotherapeuticsN/AN/A-$29.22MN/AN/AMineralys TherapeuticsN/AN/A-$177.81M-$3.73-3.79 SummaryMineralys Therapeutics beats Calidi Biotherapeutics on 8 of the 11 factors compared between the two stocks. Get Calidi Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CLDI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLDI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLDI vs. The Competition Export to ExcelMetricCalidi BiotherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$15.25M$282.85M$5.61B$21.04BDividend YieldN/AN/A4.61%3.56%P/E RatioN/AN/A30.2928.01Price / SalesN/A570.35463.4157.05Price / CashN/A22.4438.2123.95Price / Book-2.179.418.825.26Net Income-$29.22M-$115.81M$3.25B$994.11M7 Day Performance0.60%2.63%3.70%2.09%1 Month Performance-26.57%-0.34%5.84%2.35%1 Year Performance-73.58%-2.92%29.92%13.36% Calidi Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLDICalidi Biotherapeutics0.7747 of 5 stars$5.04-14.0%N/A-73.4%$15.25MN/A0.0038Short Interest ↓MLYSMineralys Therapeutics3.1881 of 5 stars$13.46+0.4%$32.25+139.6%+54.8%$874MN/A0.0028News CoverageEarnings ReportAnalyst ForecastInsider TradeZYMEZymeworks0.2404 of 5 stars$12.41-1.0%N/AN/A$873.83M$76.30M0.00460Earnings ReportLENZLENZ Therapeutics1.1227 of 5 stars$30.17-1.0%$49.60+64.4%+74.1%$869.35MN/A0.00110TRVITrevi Therapeutics3.0722 of 5 stars$7.27-1.9%$20.88+187.1%+187.0%$869.14MN/A0.0020NRIXNurix Therapeutics2.5724 of 5 stars$10.46-7.5%$28.87+176.0%-51.8%$864.64M$54.55M0.00300XERSXeris Biopharma3.4033 of 5 stars$5.49+0.2%$6.25+13.8%+186.3%$856.99M$203.07M0.00290News CoverageEarnings ReportAnalyst UpgradeInsider TradeAnalyst RevisionPHARPharming Group2.256 of 5 stars$12.29-1.5%$30.00+144.1%+45.7%$855.06M$297.20M0.00280Short Interest ↑High Trading VolumeORICOric Pharmaceuticals4.7387 of 5 stars$9.88-1.1%$18.57+88.0%+0.6%$851.39MN/A0.0080News CoverageEarnings ReportAnalyst ForecastShort Interest ↓DNAGinkgo Bioworks0.9941 of 5 stars$13.95-2.3%$8.50-39.1%N/A$835.84M$227.04M0.00640Earnings ReportGap DownUPBUpstream Bio1.8759 of 5 stars$16.72+7.9%$56.50+237.9%N/A$833.80M$2.37M0.0038 Related Companies and Tools Related Companies Mineralys Therapeutics Competitors Zymeworks Competitors LENZ Therapeutics Competitors Trevi Therapeutics Competitors Nurix Therapeutics Competitors Xeris Biopharma Competitors Pharming Group Competitors Oric Pharmaceuticals Competitors Ginkgo Bioworks Competitors Upstream Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CLDI) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Calidi Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Calidi Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.